Dual antitumor effects of 5-fluorouracil on the cell cycle in colorectal carcinoma cells: A novel target mechanism concept for pharmacokinetic modulating chemotherapy

Cancer Research

Volumn 61, Issue 3, 2001, Pages 1029-1037

  Yoshikawa, R ^a   Kusunoki, M ^a   Yanagi, H ^a   Noda, M ^a   Furuyama, J I ^a   Yamamura, T ^a   Hashimoto Tamaoki, T ^a  

^a HYOGO COLLEGE OF MEDICINE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIN B1; FLUOROURACIL; PROTEIN P53; UFT;

ADVANCED CANCER; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER CHEMOTHERAPY; CELL CYCLE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL GROWTH; CELL KINETICS; CELL POPULATION; COLORECTAL CARCINOMA; CONCENTRATION (PARAMETERS); CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG DETERMINATION; GROWTH INHIBITION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION;

ADENOCARCINOMA; ADMINISTRATION, ORAL; ANTIMETABOLITES, ANTINEOPLASTIC; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; APOPTOSIS; CELL CYCLE; CELL CYCLE PROTEINS; CELL DIVISION; COLORECTAL NEOPLASMS; DNA, NEOPLASM; DOSE-RESPONSE RELATIONSHIP, DRUG; FLOW CYTOMETRY; FLUOROURACIL; HUMANS; INFUSIONS, INTRAVENOUS; TEGAFUR; TUMOR CELLS, CULTURED; URACIL;

EID: 0035110959     PISSN: 00085472     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (62)

1. 5-Fluorouracil: Biochemistrypharmacology
2. A prospective randomized trial of fluorouracil versus fluorouracil plus cisplatin in the treatment of metastatic colorectal cancer: A Hoosier Oncology Group trial
3. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma
4. Levamisole and fluorouracil for adjuvant therapy of resected colon carcinoma
5. Leucovorin plus 5-fluorouracil: An effective treatment for metastatic colon cancer
6. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: Evidence in terms of response rate
7. Meta-analysis of randomized trials testing the biochemical modulation of fluorouracil by methotrexate in metastatic colorectal cancer
8. Sequential methotrexate, 5-fluorouracil (5-FU), and high dose leucovorin versus 5-FU and high dose leucovorin versus 5-FU alone for advanced colorectal cancer
9. Chemotherapy for colorectal carcinoma: One small step forward, one step backward
10. A prospective randomized trial of 5-fluorouracil versus 5-fluorouracil and high-dose leucovorin versus 5-fluorouracil and methotrexate in previously untreated patients with advanced colorectal carcinoma
11. The modulation of fluorouracil with leucovorin in metastatic colorectal carcinoma: A prospective randomized Phase III trial
12. Biochemical modulation of fluorouracil with leucovorin: Confirmatory evidence of improved therapeutic efficacy in advanced colorectal cancer
13. Effects of pharmacokinetic modulating chemotherapy using oral UFT and continuous venous 5-FU infusion on the prognosis of irradiated rectal carcinomas with p53 overexpression
14. The usefulness of pharmacokinetic modulating chemotherapy (UFT plus 5-FU) in the treatment of unresectable colorectal carcinomas
15. Pharmacokinetic modulation of plasma 5-fluorouracil concentration to potentiate the antitumor activity of continuous venous infusion of 5-fluorouracil
16. Correlation between dihydropyrimidine dehydrogenase activity in peripheral mononuclear cells and systemic clearance of fluorouracil in cancer patients
17. Enhancing 5-fluorouracil cytotoxicity by inhibiting dihydropyrimidine dehydrogenase activity with uracil in human tumor cells
18. p53 and the behaviour of colorectal cancer
19. Association of p53 mutations with short survival in colorectal cancer
20. Phase I trial of uracil-tegafur (UFT) plus oral leucovorin: 28-Day schedule
21. The serum and tissue concentrations of tegafur, 5-fluorouracil and uracil in the patients with gastric and colo-rectal cancers after oral administration of UFT
22. Identification and classification of p53-regulated genes
23. Checkpoints: Controls that ensure the order of cell cycle events
24. Universal control mechanism regulating onset of M-phase
25. Mitosis in transition
26. Principles of CDK regulation
27. Nuclear localization of cyclin B1 mediates its biological activity and is regulated by phosphorylation
28. Human cyclins A and B1 are differentially located in the cell and undergo cell cycle-dependent nuclear transport
29. cdc2-cyclin B complex at meiosis reinitiation in starfish oocytes
30. cdc2 kinase to microtubules and is a potential regulator of M-phase microtubule dynamics
31. Nuclear localization of cyclin B1 controls mitotic entry after DNA damage
32. Cyclin A, and B functions in the early Drosophila embryo
33. 5-Fluorouracil interferes with paclitaxel cytotoxicity against human solid tumor cells
34. p53 mutants have selective dominant-negative effects on apoptosis but not growth arrest in human cancer cell lines
35. Effects of the plasma concentration of 5-fluorouracil and the duration of continuous venous infusion of 5-fluorouracil with an inhibitor of 5-fluorouracil degradation on Yoshida sarcoma in rats
36. Screening the p53 status of human cell lines using a yeast functional assay
37. Expression and role of p27(kip1) in neuronal differentiation of embryonal carcinoma cells
38. Results of pharmacokinetic modulating chemotherapy in combination with hepatic arterial 5-FU infusion alone and oral UFT after resection of hepatic colorectal metastases
39. 14-3-3δ is required to prevent mitotic catastrophe after DNA damage
40. Fluorouracil in colorectal cancer - A tale of two drugs: Implications for biochemical modulation
41. p53 mutations in human cancers
42. The p53 tumor suppressor gene
43. WAF1, a potential mediator of p53 tumor suppression
44. 1 cyclin-dependent kinases
45. Induction of differentiation in human promyelocytic HL-60 leukemia cells activates p21, WAF1/CIP1, expression in the absence of p53
46. 1 arrest and apoptosis
47. Complementary DNA cloning of a novel epithelial cell marker protein, HME1, that may be down-regulated in neoplastic mammary cells
48. Molecular cloning and expression of the transformation sensitive epithelial marker stratifin. A member of a protein family that has been involved in the protein kinase C signaling pathway
49. 14-3-3 Proteins on the MAP
50. Molecular evolution of the 14-3-3 protein family
51. 2/M progression
52. The differential localization of human cyclins A and B is due to a cytoplasmic retention signal in cyclin B
53. CRM1 is an export receptor for leucine-rich nuclear export signals
54. CRM1 is responsible for intracellular transport mediated by the nuclear export signal
55. Evidence for a role of CRM1 in signal-mediated nuclear protein export
56. Exportin 1 (Crm1p) is an essential nuclear export factor
57. 2 checkpoint
58. Human wee1 maintains mitotic timing by protecting the nucleus from cytoplasmicly activated cdc2 kinase
59. p53 status and the efficacy of cancer therapy in vivo
60. p53 status predicts the efficacy of postoperative oral administration of tegafur for completely resected non-small cell lung cancer
61. Amplified DNA with limited homology to myc cellular oncogene is shared by human neuroblastoma cell lines and a neuroblastoma tumour
62. WAF1/CIP via C/EBPβ